# Moxidectin for LF, Cote d'Ivoire (DOLF)

> **NCT04410406** · PHASE3 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 164 (actual)

## Conditions studied

- Lymphatic Filariasis

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Diethylcarbamazine
- **DRUG:** Albendazole
- **DRUG:** Moxidectin

## Key facts

- **NCT ID:** NCT04410406
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-20
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410406, "Moxidectin for LF, Cote d'Ivoire (DOLF)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04410406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*